Aurinia Pharmaceuticals AUPH Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $34.36M+47.2% | $210.79M+14,651% | $31.55M+120% | $21.51M+2,880% | $23.34M+317% | ||
| $4.82M-0.8% | $4.86M0.0% | $4.87M-0.6% | $4.86M+0.4% | $4.86M+0.2% | ||
| -$866K+74.6% | $6.73M-24.8% | $5.92M-28.9% | $5.44M-36.6% | -$3.41M-159% | ||
| $9.28M— | —— | —— | —— | $0— | ||
| $720K-89.7% | $897K— | —— | $308K+134% | $6.97M+12,341% | ||
| -$652K+33.1% | —— | -$1.1M-337% | -$901K-133% | -$974K-172% | ||
| -$5.59M+76.1% | —— | -$641K-91.9% | —— | -$23.41M-195% | ||
| -$581K+75.0% | $5.05M+989% | -$720K— | -$1.81M— | -$2.33M-49.1% | ||
| $1.08M-75.1% | —— | —— | $805K+226% | $4.34M+144,833% | ||
| -$950K+84.3% | -$4.58M— | —— | —— | -$6.03M-591% | ||
| -$214K-9.7% | -$202K-1.0% | -$205K-10.8% | -$200K-8.7% | -$195K-7.7% | ||
| $7.72M+103% | $10.73M+17,484% | -$9.36M-185% | $0— | $3.81M-21.0% | ||
| $32.56M+2,405% | $45.67M+51.7% | $44.45M+161% | $44.24M+179% | $1.3M+107% | ||
| -$18.08M-158% | -$36.76M-194% | —— | —— | $31.03M-37.0% | ||
| $36.17M-22.9% | $0-100% | $8.67M— | $42.56M+594% | $46.92M+281% | ||
| $713K-92.3% | $355K-6.8% | —— | —— | $9.29M+68.1% | ||
| $3.65M+31.8% | $3.49M+15.1% | $3.45M+16.6% | $6.2M+3.3% | $2.77M-0.3% | ||
| $14.58M+63.2% | $364K+50.4% | $364K+118% | $103K-55.0% | $8.93M+62.5% | ||
| -$53.69M-8.8% | -$1.89M+91.8% | -$10.49M-285% | -$44.39M-437% | -$49.34M-228% | ||
| -$39.21M-131% | —— | —— | -$13.43M+56.8% | -$17.01M-209% | ||
| $1.33M+439% | $0-100% | $2.03M— | $820K-43.8% | $246K— | ||
| $2.32M-12.7% | $2.34M-21.6% | $2.63M-23.3% | $2.56M-18.0% | $2.66M-17.2% | ||
| $416K+123% | -$367K-107% | -$53K— | -$7.45M— | -$1.81M-130% | ||
| -$5.59M+76.1% | —— | -$641K-91.9% | —— | -$23.41M-195% | ||
| -$214K-9.7% | -$202K-1.0% | -$205K-10.8% | -$200K-8.7% | -$195K-7.7% | ||
| -$950K+84.3% | -$4.58M— | —— | —— | -$6.03M-591% | ||
| -$581K+75.0% | $5.05M+989% | -$720K— | -$1.81M— | -$2.33M-49.1% | ||
| $39K+129% | $72K+28.6% | $65K-23.5% | $98K-23.4% | $17K+41.7% | ||
| $3.65M+31.8% | $3.49M+15.1% | $3.45M+16.6% | $6.2M+3.3% | $2.77M-0.3% | ||
| -$214K-9.7% | -$202K-1.0% | -$205K-10.8% | -$200K-8.7% | -$195K-7.7% | ||
| —— | $943.25K— | $943.25K— | $943.25K— | $943.25K— | ||
| $1.33M+439% | $0-100% | $2.03M— | $820K-43.8% | $246K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Aurinia Pharmaceuticals's cash flow data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.